Among these, the epidermal growth factor receptor (EGFR) is the most extensively studied biomarker in lung cancer, encompassing multiple mutations that assist clinicians in optimizing therapeutic decisions, including the initiation [5,11] or discontinuation of targeted treatments [12]. This evidence concerns the gene EGFR and lung carcinoma.